Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 58, Issue 5, Pages 817-820Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2011.04.030
Keywords
Nephrotoxicity; pemetrexed; tubulointerstitial injury
Categories
Ask authors/readers for more resources
Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer. Major side effects include myelosuppression and neutropenia. Three patients developed kidney disease while being treated with maintenance pemetrexed. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case. Kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy in all cases. Am J Kidney Dis. 58(5):817-820. (C) 2011 by the National Kidney Foundation, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available